



(12) **United States Patent**
Hayer et al.

(10) **Patent No.:** **US 10,471,115 B2**
(45) **Date of Patent:** ***Nov. 12, 2019**

(54) **COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH**

(71) Applicant: **KIDNEY STONE RESEARCH COMPANY, INC.**, Fort Lauderdale, FL (US)

(72) Inventors: **Gregory K. Hayer**, Fort Lauderdale, FL (US); **Brendan Magrab**, Westfield, NJ (US); **Henry R. Wolfe, Jr.**, Glenmoore, PA (US)

(73) Assignee: **KIDNEY STONE RESEARCH COMPANY, INC.**, Fort Lauderdale, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 55 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/710,306**

(22) Filed: **Sep. 20, 2017**

(65) **Prior Publication Data**
US 2018/0008660 A1 Jan. 11, 2018

Related U.S. Application Data

(60) Continuation of application No. 15/487,735, filed on Apr. 14, 2017, now Pat. No. 9,789,152, which is a continuation of application No. 15/266,464, filed on Sep. 15, 2016, now Pat. No. 9,623,066, which is a division of application No. 15/059,644, filed on Mar. 3, 2016, now Pat. No. 9,492,491, which is a continuation-in-part of application No. 14/960,692, filed on Dec. 7, 2015, now abandoned, which is a continuation of application No. 14/845,612, filed on Sep. 4, 2015, now Pat. No. 9,233,135.

(51) **Int. Cl.**
A61K 36/00 (2006.01)
A61K 36/88 (2006.01)
A61K 31/194 (2006.01)
A61K 33/06 (2006.01)
A61K 31/6615 (2006.01)
A61K 31/4415 (2006.01)
A61K 9/48 (2006.01)
A61K 9/00 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 36/88** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/48** (2013.01); **A61K 9/4858** (2013.01); **A61K 31/194** (2013.01); **A61K 31/4415** (2013.01); **A61K 31/6615** (2013.01); **A61K 33/06** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2009/0068255 A1* 3/2009 Yu A61K 8/0212 424/450
2013/0302448 A1* 11/2013 Parc A23L 1/302 424/725
2013/0337057 A1 12/2013 Patankar
2014/0272068 A1* 9/2014 Prakash A23L 2/60 426/548

FOREIGN PATENT DOCUMENTS

RO 80051 A2 * 10/1982

OTHER PUBLICATIONS

Prasobh et al, A study on the use of musa species in the management of renal calculi. Asian Journal of Pharmaceutical and Clinical Research, (Jul.-Sep. 2014) vol. 7, No. 3, pp. 123-125.*
“Highlights of Prescribing Information:UROCIT-K (Potassium Citrate)”;Mission Pharmacal Company; Dec. 2009; 2 pages.
“Kidney stones”;Magnesium online resource center;2007-2008;[retrieved Aug. 19, 2015 from http://www.mg12.info/articles/kidney-stones.html]; 2 pages.
Abirami J et al.; “Evaluation of Toxicity Profiles of *Musa paradisiaca* L (Pseudostem) Juice”; International Journal of Pharmacy and Pharmaceutical Sciences; vol. 6, Sup. 1; 2014; pp. 9-11.
Devi et al.; “Biochemical Effects in Normal and Stone Forming Rats Treated With the Ripe Kernel Juice of Plantain (*Musa paradisiaca*)”; Ancient Science of Life, Vol No. XII,Nos. 3 & 4; 1993; pp. 451-461.
Duan; “Changes in urinary nanocrystallites in calcium oxalate stone formers before and after potassium citrate intake”; International Journal of Nanomedicine,vol. 8; 2013; pp. 909-918.
Ebisuno et al.; “Results of long-term rice bran treatment on stone recurrence in hypercalciuric patients”; Br J Urol.; vol. 67, No. 3; 1991; pp. 237-240 (Abstract Only).
Ebisuno et al.; “Rice-bran Treatment for Calcium Stone Formers with Idiopathic Hypercalciuria”; British Journal of Urology; vol. 58, No. 6; 1986; pp. 592-595 (Abstract Only).
Grases et al.; “Influence of Concomitant Food Intake on the Excretion of Orally Administered myo-Inositol Hexaphosphate in Humans”; J Med Food vol. 9, No. 1; 2006; pp. 72-76.
Jha U et al.;“Pharmacological Screening of *Musa paradisiaca* Linn Against Ethylene Glycol Induced Renal Calculi”; International Journal of Research in Ayurveda & Pharmacy, vol. 2, No. 3; 2011; pp. 995-998.
Kalpana et al. ; “Inhibition of Calcium Oxalate Crystallization In Vitro by Extract of Banana Cultivar Monthan”; International Journal of Pharmacy and Pharmaceutical Sciences, vol. 5, No. 4; 2013; pp. 349-653.
Khan et al.;“Antirolithic activity of *Origanum vulgare* is mediated through multiple pathways”; BMC Complementary and Alternative Medicine; vol. 11, No. 96; 2011; 16 pages.

(Continued)

Primary Examiner — Qiuwen Mi
(74) *Attorney, Agent, or Firm* — Cantor Colburn LLP

(57) **ABSTRACT**

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.